NCT07521358 (MAG-DEP) is a NA clinical trial of Fluoxetine (drug) in Major Depressive Disorder (MDD), sponsored by Hasanuddin University.

Who is sponsoring NCT07521358?

NCT07521358 is sponsored by Hasanuddin University.

What drugs are being tested in NCT07521358?

Interventions in NCT07521358: Fluoxetine (drug), Magnesium.

What condition does NCT07521358 study?

NCT07521358 studies Major Depressive Disorder (MDD).

Is NCT07521358 still recruiting?

NCT07521358 is currently completed. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT07521358: MAG-DEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium Supplementation With Fluoxetine for Cognitive Function in Depression

Completed NA Last updated 9 April 2026

What this trial tests

NA trial testing Fluoxetine (drug) in Major Depressive Disorder (MDD) in 40 participants. Completed in 1 August 2025.

Timeline

1 July 2025

Primary endpoint
1 August 2025

1 August 2025

Quick facts

Lead sponsor	Hasanuddin University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	1 July 2025
Primary completion	1 August 2025
Estimated completion	1 August 2025
Sites	1 location across Indonesia

Drugs / interventions tested

Fluoxetine (drug) — full drug profile →
Magnesium — full drug profile →

Conditions studied

Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →

Sponsor

Hasanuddin University

Who can join

Adults 18 to 60, any sex, with Major Depressive Disorder (MDD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate whether magnesium supplementation can improve cognitive function in patients with depression receiving fluoxetine therapy. It also aims to assess its effect on serum brain-derived neurotrophic factor (BDNF) levels in adult patients with depression. The main questions it aims to answer are: * Does magnesium supplementation improve cognitive function in patients with depression receiving fluoxetine? * Does magnesium supplementation increase serum BDNF levels in these patients? Researchers will compare patients receiving fluoxetine with magnesium supplementation to those receiving fluoxetine alone to determine whether magnesium provides additional benefits. Participants will: * Receive fluoxetine therapy with or without magnesium supplementation for 6 weeks * Undergo cognitive assessment using the Montreal Cognitive Assessment (MoCA) at baseline and after treatment * Provide blood samples for measurement of serum BDNF levels at baseline and after 6 weeks

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Fluoxetine (drug)

Trials testing the same drug.

NCT07174947 — SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depre · Phase 2 · recruiting

Other recruiting trials for Major Depressive Disorder (MDD)

Currently open trials in the same condition.

NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
NCT07294924 — Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements · recruiting

Other Hasanuddin University trials

Trials by the same sponsor.

NCT07479394 — Impact of AHCC® Supplementation for Prevention of Respiratory Tract Infections Among Children Age 2-4 Years Old · Phase 4 · not yet recruiting
NCT07524868 — Effect of Cognitive Behavioral Therapy on Auditory Hallucinations and NLR in Schizophrenia Patients · NA · completed
NCT07440264 — Theta Brainwave Entrainment Combined With Natural Sound on Healthcare Shift Workers With Poor Sleep Quality: A Randomize · NA · completed
NCT07272993 — Effect of Golden Rice-Piper Crocatum Cookies on Neuropathy Prevention in Diabetes · NA · active not recruiting
NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07521358 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hasanuddin University
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07521358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing